Infinimmune unveiled $75 million in Series A financing to advance two atopic dermatitis antibody programs into clinical testing.
- Amount
- $75M
- Stage
- Series A
- Announced
- 11 August 2026
- Use of funds
- Supporting clinical research for two lead programs entering the clinic in atopic dermatitis.
- Checked
- Amount and date checked against the press source